Muscular Dystrophy Defect Drug Comes a Step Closer to Reality

The atomic-level view of a genetic defect that causes a form of muscular dystrophy has now been discovered by a team of researchers.

The scientists from The Scripps Research Institute have used this information to design drug candidates with potential to counter those defects and reverse the disease.

Genetic Editing Shows Promise in Duchenne Muscular Dystrophy: Research
Duke University biomedical engineers have been able to repair a defect responsible for one of the most common inherited disorders, Duchenne muscular dystrophy.

"This the first time the structure of the RNA defect that causes this disease has been determined," lead author Matthew Disney said. "Based on these results, we designed compounds that, even in small amounts, significantly improve disease-associated defects in treated cells."

Myotonic dystrophy type 2 is a relatively rare form of muscular dystrophy that is somewhat milder than myotonic dystrophy type 1, the most common adult-onset form of the disease.

Both types of myotonic dystrophy are inherited disorders that involve progressive muscle wasting and weakness, and both are caused by a type of genetic defect known as a "RNA repeat expansion," a series of nucleotides repeated more times than normal in an individual's genetic code.

Hope For Patients With Muscular Dystrophy
Researchers are now saying that the gene known as “mighty mouse” might be beneficial in human cells as well. Studies on this gene arose when a

The repeat binds to the protein MBNL1, rendering it inactive and resulting in RNA splicing abnormalities-which lead to the disease.

Using information about the RNA's structure and movement, the scientists were able to design molecules to improve RNA function.

Switching Genes to Overdrive Improves Muscular Dystrophy Symptoms in Mice
Scientists at Dana-Farber Cancer Institute have shown in a laboratory study that revving up a crucial set of muscle genes

The new findings were confirmed using sophisticated computational models that show precisely how the small molecules interact with and alter the RNA structure over time.

Those predictive models matched what the scientists found in the study-that these new compounds bind to the repeat structure in a predictable and easily reproducible way, attacking the cause of the disease.

The study is published in journal ACS Chemical Biology.

Source-ANI